Loading clinical trials...
Loading clinical trials...
An Exploratory Clinical Study of Low-dose Gemcitabine Combined With Nivolumab for Second-line and Higher-line Treatment of Driving Gene-negative Non-small Cell Lung Cancer
Conditions
Interventions
Gemcitabine Injectable Product
Start Date
April 1, 2020
Primary Completion Date
December 1, 2022
Completion Date
April 1, 2023
Last Updated
April 2, 2020
NCT07250477
NCT06517953
NCT04563338
NCT04163432
NCT04504071
NCT03469960
Lead Sponsor
Henan Cancer Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions